147 related articles for article (PubMed ID: 34176597)
1. Depression as a Driving Force for Low Time in Therapeutic Range and Dementia in Patients With and Without Atrial Fibrillation.
Rizzi SA; Knight S; May HT; Woller SC; Stevens SM; Steinberg BA; Bair TL; Anderson JL; Muhlestein JB; Knowlton KU; Bunch TJ
Am J Cardiol; 2021 Aug; 153():58-64. PubMed ID: 34176597
[TBL] [Abstract][Full Text] [Related]
2. Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications.
Bunch TJ; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Jacobs V; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27402230
[TBL] [Abstract][Full Text] [Related]
3. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry.
Pokorney SD; Simon DN; Thomas L; Fonarow GC; Kowey PR; Chang P; Singer DE; Ansell J; Blanco RG; Gersh B; Mahaffey KW; Hylek EM; Go AS; Piccini JP; Peterson ED;
Am Heart J; 2015 Jul; 170(1):141-8, 148.e1. PubMed ID: 26093875
[TBL] [Abstract][Full Text] [Related]
4. Time outside of therapeutic range in atrial fibrillation patients is associated with long-term risk of dementia.
Jacobs V; Woller SC; Stevens S; May HT; Bair TL; Anderson JL; Crandall BG; Day JD; Johanning K; Long Y; Mallender C; Olson JL; Osborn JS; Weiss JP; Bunch TJ
Heart Rhythm; 2014 Dec; 11(12):2206-13. PubMed ID: 25111326
[TBL] [Abstract][Full Text] [Related]
5. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Warfarin Anticoagulation and Incident Dementia in a Community-Based Cohort of Atrial Fibrillation.
Madhavan M; Hu TY; Gersh BJ; Roger VL; Killian J; Weston SA; Graff-Radford J; Asirvatham SJ; Chamberlain AM
Mayo Clin Proc; 2018 Feb; 93(2):145-154. PubMed ID: 29329798
[TBL] [Abstract][Full Text] [Related]
7. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
Van Spall HG; Wallentin L; Yusuf S; Eikelboom JW; Nieuwlaat R; Yang S; Kabali C; Reilly PA; Ezekowitz MD; Connolly SJ
Circulation; 2012 Nov; 126(19):2309-16. PubMed ID: 23027801
[TBL] [Abstract][Full Text] [Related]
8. The impact of new-onset cancer among veterans who are receiving warfarin for atrial fibrillation and venous thromboembolism.
Ambrus DB; Reisman JI; Rose AJ
Thromb Res; 2016 Aug; 144():21-6. PubMed ID: 27270218
[TBL] [Abstract][Full Text] [Related]
9. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting.
Urbonas G; Valius L; Šakalytė G; Petniūnas K; Petniūnienė I
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30650565
[No Abstract] [Full Text] [Related]
10. Stability of High-Quality Warfarin Anticoagulation in a Community-Based Atrial Fibrillation Cohort: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.
Dallalzadeh LO; Go AS; Chang Y; Borowsky LH; Fang MC; Singer DE
J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27451456
[TBL] [Abstract][Full Text] [Related]
11. Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction.
Szummer K; Gasparini A; Eliasson S; Ärnlöv J; Qureshi AR; Bárány P; Evans M; Friberg L; Carrero JJ
J Am Heart Assoc; 2017 Mar; 6(3):. PubMed ID: 28249846
[TBL] [Abstract][Full Text] [Related]
12. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
[TBL] [Abstract][Full Text] [Related]
13. Relation of gender-specific risk of ischemic stroke in patients with atrial fibrillation to differences in warfarin anticoagulation control (from AFFIRM).
Sullivan RM; Zhang J; Zamba G; Lip GY; Olshansky B
Am J Cardiol; 2012 Dec; 110(12):1799-802. PubMed ID: 22995971
[TBL] [Abstract][Full Text] [Related]
14. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
Singer DE; Hellkamp AS; Piccini JP; Mahaffey KW; Lokhnygina Y; Pan G; Halperin JL; Becker RC; Breithardt G; Hankey GJ; Hacke W; Nessel CC; Patel MR; Califf RM; Fox KA;
J Am Heart Assoc; 2013 Feb; 2(1):e000067. PubMed ID: 23525418
[TBL] [Abstract][Full Text] [Related]
15. Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.
Piccini JP; Hellkamp AS; Lokhnygina Y; Patel MR; Harrell FE; Singer DE; Becker RC; Breithardt G; Halperin JL; Hankey GJ; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM;
J Am Heart Assoc; 2014 Apr; 3(2):e000521. PubMed ID: 24755148
[TBL] [Abstract][Full Text] [Related]
16. INR variability and outcomes in patients with mechanical heart valve prosthesis.
Labaf A; Själander A; Stagmo M; Svensson PJ
Thromb Res; 2015 Dec; 136(6):1211-5. PubMed ID: 26558830
[TBL] [Abstract][Full Text] [Related]
17. Quality of warfarin management in primary care: Determining the stability of international normalized ratios using a nationally representative prospective cohort.
Liu S; Singer A; McAlister FA; Peeler W; Heran BS; Drummond N; Manca DP; Allan GM; Korownyk C; Kolber MR; Greiver M; Garrison SR
Can Fam Physician; 2019 Jun; 65(6):416-425. PubMed ID: 31189630
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
[TBL] [Abstract][Full Text] [Related]
19. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics, Oral Anticoagulation Patterns, and Outcomes of Medicaid Patients With Atrial Fibrillation: Insights From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF I) Registry.
O'Brien EC; Kim S; Thomas L; Fonarow GC; Kowey PR; Mahaffey KW; Gersh BJ; Piccini JP; Peterson ED
J Am Heart Assoc; 2016 May; 5(5):. PubMed ID: 27146448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
